In 2019,Multiple sclerosis (Houndmills, Basingstoke, England) included an article by Couloume, Laura; Barbin, Laetitia; Leray, Emmanuelle; Wiertlewski, Sandrine; Le Page, Emmanuelle; Kerbrat, Anne; Ory, Solenn; Le Port, Damien; Edan, Gilles; Laplaud, David-Axel; Michel, Laure. Related Products of 58-85-5. The article was titled 《High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.》. The information in the text is summarized as follows:
BACKGROUND: A recent controlled trial suggested that high-dose biotin supplementation reverses disability progression in patients with progressive multiple sclerosis. OBJECTIVE: To analyze the impact of high-dose biotin in routine clinical practice on disability progression at 12 months. METHODS: Progressive multiple sclerosis patients who started high-dose biotin at Nantes or Rennes Hospital between 3 June 2015 and 15 September 2017 were included in this prospective study. Disability outcome measures, patient-reported outcome measures, relapses, magnetic resonance imaging (MRI) data, and adverse events were collected at baseline, 6, and 12 months. RESULTS: A total of 178 patients were included. At baseline, patients were 52.0 ± 9.4 years old, mean Expanded Disability Status Scale (EDSS) score was 6.1 ± 1.3, mean disease duration was 16.9 ± 9.5 years. At 12 months, 3.8% of the patients had an improved EDSS score. Regarding the other disability scales, scores either remained stable or increased significantly. In total, 47.4% of the patients described stability, 27.6% felt an improvement, and 25% described a worsening. Four patients (2.2%) had a relapse. Of the 74 patients (41.6%) who underwent an MRI, 20 (27.0%) had new T2 lesions, 8 (10.8%) had gadolinium-enhancing lesions. Twenty-five (14%) reported adverse event. CONCLUSION: In this study, high-dose biotin did not seem to be associated with a clear improvement in disability. The experimental part of the paper was very detailed, including the reaction process of 5-((3aS,4S,6aR)-2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid(cas: 58-85-5Related Products of 58-85-5)
5-((3aS,4S,6aR)-2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid(cas: 58-85-5) may be used to elute proteins from avidin/streptavidin resins. It has been used for culturing of oligodendrocytes.Related Products of 58-85-5 And it has been used for blocking endogenous biotin during immunohistology procedures.
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem